Summary: New experimental evidence indicates that circulating blood factors influence Alzheimer’s disease progression. In a long-term study, mice predisposed to develop Alzheimer’s-like pathology received weekly transfusions of blood from either young or aged donor mice. Blood from older animals accelerated amyloid accumulation and cognitive decline, while young blood showed protective molecular and behavioral effects.
The study combined behavioral testing, histological and biochemical analysis of amyloid plaques, and large-scale proteomics. Researchers identified more than 250 brain proteins whose levels shifted depending on donor age, implicating pathways tied to synaptic signaling, calcium regulation, and the endocannabinoid system. These results support the idea that specific blood-borne molecules could become targets for future Alzheimer’s therapies or prevention strategies.
Key Facts
- Blood-borne influence: Aged blood sped up amyloid plaque buildup and worsened cognitive performance in an Alzheimer’s mouse model.
- Protective potential: Young blood altered brain protein networks in ways consistent with improved synaptic and neuronal function.
- Therapeutic implications: Circulating factors in blood represent a promising avenue for developing interventions that act through the blood–brain axis.
Source: Melisa Institute
Alzheimer’s disease is the most common form of dementia and a leading public health challenge worldwide. Characterized by abnormal accumulation of beta-amyloid (Aβ) protein that forms plaques and disrupts neuronal communication, Alzheimer’s progression may also be influenced by systemic factors that travel through the blood.
To investigate whether circulating blood components can modify brain amyloidosis, researchers from Instituto Latinoamericano de Salud Cerebral (BrainLat) at Universidad Adolfo Ibáñez, MELISA Institute, the University of Texas Health Science Center at Houston, and Universidad Mayor conducted a 30-week transfusion study using Tg2576 transgenic mice, a standard animal model of Alzheimer’s pathology. These mice received weekly infusions of blood from either young or aged wild-type donors.
Behavioral testing with the Barnes maze revealed that animals receiving aged blood showed poorer spatial memory and learning compared with those receiving blood from young donors. Post-mortem analysis demonstrated increased Aβ plaque burden in the brains of mice exposed to aged blood. Conversely, mice treated with young blood displayed protein expression patterns linked to healthier synaptic signaling.
A comprehensive proteomic survey of treated brains identified over 250 differentially expressed proteins. Affected pathways included synaptogenesis, endocannabinoid signaling, and proteins that regulate calcium channels—molecular systems critical for neuronal communication and survival. Among the proteins highlighted was α2δ2, a component related to calcium channel function, which the authors validated as a potential mediator of blood-driven effects on neuronal health.
“This collaborative work underscores how systemic, peripheral signals shape the brain’s environment and can directly influence mechanisms that drive Alzheimer’s pathology,” said Dr. Claudia Durán-Aniotz of BrainLat. “Demonstrating that factors in aged blood can modulate central nervous system processes opens new avenues to explore therapeutic strategies that target the blood–brain axis.”
Mauricio Hernández of the MELISA Institute, who led the proteomic analyses, noted the technical challenges of working with complex biological matrices like plasma. Using advanced instrumentation, the team produced high-quality proteomic data that strengthened the study’s conclusions.
These findings reinforce the concept that circulating molecules contribute to neurodegenerative disease progression and suggest that identifying the specific harmful or protective factors in blood could reveal new targets for intervention. The next research steps are to isolate and characterize the responsible molecules and to assess whether similar mechanisms operate in humans.
Dr. Elard Koch, Chairman of MELISA Institute, emphasized the importance of supporting proteomic and translational research to accelerate discovery of therapies for neurodegenerative disorders, which remain a global health priority.
Funding:
The research received support from multiple funding sources, including grants to C.DA. (ANID/FONDECYT Regular 1210622; ANID/PIA/ANILLOS ACT210096), the Alzheimer’s Association, ReDLat (supported by NIH R01AG057234 and other partners), the Rainwater Charitable Foundation, the Global Brain Health Institute, and additional NIH awards and contracts. Additional contributions were supported by NIH grants RF1AG072491 and RF1AG059321, and ANID/FONDECYT Regular 1240176. The authors note that the content reflects their views and not necessarily those of the funding agencies.
Key Questions Answered:
A: Mice receiving blood from older donors accumulated amyloid plaques more rapidly, exhibited altered brain protein profiles, and performed worse on cognitive tests—findings that indicate circulating factors in aged blood promote processes associated with Alzheimer’s progression.
A: Young blood shifted brain protein expression toward patterns linked with healthy synaptic signaling and reduced markers of disease-related dysfunction, suggesting protective molecular effects that may slow neurodegeneration.
A: The study highlights the blood–brain axis as a meaningful contributor to Alzheimer’s progression. Identifying the exact blood-borne molecules involved could enable novel therapeutic or preventive strategies that modify systemic factors rather than focusing solely on brain-targeted interventions.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The cited journal paper was reviewed in full by editorial staff.
- Context and explanatory detail were added by the editorial team.
About this Alzheimer’s disease research news
Author: Damian Vallejos
Source: Melisa Institute
Contact: Damian Vallejos – Melisa Institute
Image: Image credit: Neuroscience News
Original Research: Open access. “Infusion of blood from young and old mice modulates amyloid pathology” by Claudia Durán-Aniotz et al., published in Aging-US (DOI provided in the original article).
Abstract
Infusion of blood from young and old mice modulates amyloid pathology
Alzheimer’s disease is a neurodegenerative disorder marked by accumulation of misfolded proteins in the brain. Recent attention has focused on how blood-borne components may influence disease progression. This study evaluated the effects of transfusing blood from young and old wild-type mice into transgenic mice modeling Alzheimer’s-type amyloidosis.
Mice infused with blood from aged donors displayed impaired memory and greater Aβ accumulation. Proteomic profiling of treated brains revealed changes in proteins involved in synaptogenesis and the endocannabinoid system. The α2δ2 protein, involved in neuronal calcium regulation, was validated as a plausible mediator of these effects. Overall, the findings emphasize the role of circulating factors in Alzheimer’s pathology and point to potential therapeutic targets.